Business Wire

Celgene Announces Phase 3 STYLE Study of OTEZLA® (apremilast) in Moderate to Severe Scalp Psoriasis Met Primary Endpoint

Jaa

Celgene Corporation (NASDAQ:CELG) today announced results from the phase 3 STYLE study, which showed that OTEZLA® (apremilast) 30 mg twice daily achieved a highly statistically significant improvement in the primary endpoint of the Scalp Physician’s Global Assessment (ScPGA) response [defined as ScPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline] at week 16 compared with placebo.

In addition to achieving the primary endpoint, statistical significance was also met for the secondary endpoint of the whole body itch numeric rating scale (NRS) [defined as at least a 4-point reduction from baseline] at week 16 with OTEZLA versus placebo.

The safety profile was generally consistent with the known safety profile of OTEZLA, and no new safety signals were identified in the trial. Treatment-emergent adverse events that occurred in at least 5 percent of patients in either treatment group were diarrhea (30.5 percent for OTEZLA and 10.8 percent for placebo), nausea (21.5 percent and 5.9 percent, respectively), headache (11.5 percent and 4.9 percent) and vomiting (5.5 percent and 2.0 percent).

“The scalp is the most commonly affected area in moderate to severe plaque psoriasis, impacting up to 80 percent of patients,” said Terrie Curran, President, Celgene Inflammation and Immunology. “The area is difficult to treat with topical therapies, and clinical data from systemic therapies are limited. We are encouraged by the significant improvements in this trial and look forward to sharing these data to further enhance the OTEZLA label.”

About STYLE

STYLE is a phase 3, multicenter, randomized, placebo-controlled, double-blind study evaluating the efficacy and safety of OTEZLA in subjects with moderate to severe plaque psoriasis of the scalp. The study enrolled 303 people who were randomized 2:1 to receive OTEZLA 30 mg twice daily or placebo for the first 16 weeks.

About Plaque Psoriasis

Psoriasis affects 125 million people worldwide, including around 14 million people in Europe and 7.5 million people in the United States. It is a chronic and systemic inflammatory disorder, and is immune-mediated, meaning it is caused by an immune reaction in the body.

Psoriasis lesions can often be found on areas close to the joints such as the elbows and knees but can also appear on the scalp. Nail psoriasis affects up to 50 percent of people with psoriasis. Up to 84 percent of people with psoriasis experience itching, and over a third of patients cite itch as the most important factor contributing to their disease.

Around 75 percent of people living with psoriasis believe it has a negative impact on their quality of life, and 83 percent of patients with psoriasis actively conceal the visible signs of their disease.

About OTEZLA ® (apremilast)

OTEZLA® (apremilast) 30 mg tablets is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels, which is thought to indirectly modulate the production of inflammatory mediators. The specific mechanism(s) by which OTEZLA exerts its therapeutic action in patients is not well defined.

U.S. PRESCRIBING INFORMATION

INDICATION

OTEZLA® (apremilast) is indicated for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

IMPORTANT SAFETY INFORMATION

Contraindications

OTEZLA® (apremilast) is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation

Warnings and Precautions

Diarrhea, Nausea and Vomiting: Cases of severe diarrhea, nausea, and vomiting were associated with the use of OTEZLA. Most events occurred within the first few weeks of treatment. In some cases, patients were hospitalized. Patients 65 years of age or older and patients taking medications that can lead to volume depletion or hypotension may be at a higher risk of complications from severe diarrhea, nausea, or vomiting. Monitor patients who are more susceptible to complications of diarrhea or vomiting; advise patients to contact their healthcare provider. Consider OTEZLA dose reduction or suspension if patients develop severe diarrhea, nausea, or vomiting

Depression: Carefully weigh the risks and benefits of treatment with OTEZLA for patients with a history of depression and/or suicidal thoughts/behavior, or in patients who develop such symptoms while on OTEZLA. Patients, caregivers, and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes, and they should contact their healthcare provider if such changes occur

Psoriasis: Treatment with OTEZLA is associated with an increase in depression. During clinical trials, 1.3% (12/920) of patients reported depression compared to 0.4% (2/506) on placebo; Depression was reported as serious in 0.1% (1/1308) of patients exposed to OTEZLA, compared to none in placebo-treated patients (0/506). Suicidal behavior was observed in 0.1% (1/1308) of patients on OTEZLA, compared to 0.2% (1/506) on placebo. One patient treated with OTEZLA attempted suicide; one patient on placebo committed suicide

Weight Decrease: Monitor body weight regularly; evaluate unexplained or clinically significant weight loss, and consider discontinuation of OTEZLA

Psoriasis: Body weight loss of 5-10% occurred in 12% (96/784) of patients treated with OTEZLA and in 5% (19/382) of patients treated with placebo. Body weight loss of ≥10% occurred in 2% (16/784) of patients treated with OTEZLA compared to 1% (3/382) of patients treated with placebo

Drug Interactions: Apremilast exposure was decreased when OTEZLA was co-administered with rifampin, a strong CYP450 enzyme inducer; loss of OTEZLA efficacy may occur. Concomitant use of OTEZLA with CYP450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended

Adverse Reactions

Psoriasis: Adverse reactions reported in ≥5% of patients were (OTEZLA%, placebo%): diarrhea (17, 6), nausea (17, 7), upper respiratory tract infection (9, 6), tension headache (8, 4), and headache (6, 4)

Use in Specific Populations

Pregnancy and Nursing Mothers: OTEZLA is Pregnancy Category C; it has not been studied in pregnant women. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether apremilast or its metabolites are present in human milk. Caution should be exercised when OTEZLA is administered to a nursing woman

Renal Impairment: OTEZLA dosage should be reduced in patients with severe renal impairment (creatinine clearance less than 30 mL/min); for details, see Dosage and Administration, Section 2, in the Full Prescribing Information

Please  click here  for Full Prescribing Information.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next‐generation solutions in protein homeostasis, immuno‐oncology, epigenetics, immunology and neuro‐inflammation. For more information, please visit www.celgene.com. Follow Celgene on Social Media: @CelgenePinterestLinkedInFacebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the U.S. Securities and Exchange Commission.

Hyperlinks are provided as a convenience and for informational purposes only. Celgene bears no responsibility for the security or content of external websites.

Contact information

Celgene Corporation
Investors:
Nina Goworek, 908-673-9711
Executive Director, Investor Relations
or
Media:
Catherine Cantone, 908-897-4256
Senior Director, Corporate Communications

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Huawei Enters into MPEG LA’s AVC Patent Portfolio License19.2.2019 17:00:00Tiedote

MPEG LA announced today that Huawei Technologies Co., Ltd., Huawei Device Co., Ltd and Huawei Device (Shenzhen) Co., Ltd (“Huawei”) have become Licensees to MPEG LA’s AVC Patent Portfolio License (“AVC License”). As a result of this agreement, all legal disputes related to patent enforcement actions brought by patent holders in MPEG LA’s AVC License against Huawei have been resolved. See https://www.mpegla.com/wp-content/uploads/2018/12/FINAL-Huawei-ZTE-Infringement-PrsRls-2018-11-16.pdf; and https://www.mpegla.com/wp-content/uploads/2019/02/FINAL-PrsRls-2018-12-27.pdf. MPEG LA, LLC MPEG LA is the world’s leading provider of one-stop licenses for standards and other technology platforms. Starting in the 1990s, it pioneered the modern-day patent pool helping to produce the most widely used standards in consumer electronics history. MPEG LA has operated licensing programs for a variety of technologies consisting of nearly 20,000 patents in 90 countries with more than 250 patent holders a

Head Position During Sleep Has Potential Implications for Neurodegenerative Disease19.2.2019 17:00:00Tiedote

Could sleeping on your back increase your brain's risk of developing neurodegenerative disease? That possibility is revealed in a new study published in the Journal of Alzheimer's Disease. "We compared the in-home sleep patterns of patients with memory impairment resulting from neurodegenerative diseases to a large group of elderly with normal cognition," stated Daniel J. Levendowski, the study's first author and President of Advanced Brain Monitoring. "Sleeping more than 2 hours with one's head lying face upward (i.e., supine) was a significant nocturnal marker that characterized those with memory impairment, after controlling for factors such as age, sex, snoring, obstructive sleep apnea, and movements during the night." These results corroborate in humans a finding observed in rats by researchers at Stony Brook University and published in the Journal of Neuroscience. Using dynamic contrast MRI, they found that the clearance of neurotoxic proteins from the brain by glymphatic transpo

Ahearn & Soper Finds that ExaGrid Stands Behind Its Scalable System19.2.2019 17:00:00Tiedote

ExaGrid®, a leading provider of intelligent hyperconverged storage for backup, today announced that Ahearn & Soper has optimized and further protected its backup environment by establishing offsite replication using ExaGrid hyperconverged backup with data deduplication, and has been able to match its data growth due to ExaGrid’s scalable architecture. Ahearn & Soper Inc. provides barcode software and hardware solutions that improve accuracy, tracking, and efficiency within distribution, manufacturing, and healthcare operations. The company is headquartered in Toronto, Ontario, and operates across North America from branch sales and service offices. Ahearn & Soper decided to add disaster recovery (DR) to its backup environment and wanted a solution that provided offsite replication. “ExaGrid came to our site and explained how the system worked and the benefits of its architecture. We were quite impressed with the product because of the self-contained nature of the system and how it hand

Airspan Introduces 5G Millimeter Wave RAN Infrastructure Utilizing the Qualcomm FSM100xx 5G Platform19.2.2019 16:36:00Tiedote

Airspan Networks Inc. is excited to announce today that they will be expanding their cooperation with Qualcomm Technologies, Inc., a subsidiary of Qualcomm Incorporated, to include the development of 5G NR mmWave RAN solutions, leveraging the Qualcomm FSM100xx 5G Platform. This comes in the wake of the joint multi-award-winning success in 4G for the Sprint Magic Box and Reliance Jio’s ground-breaking ultra-dense Greenfield network. Airspan has deployed close to half a million small cells worldwide based on the powerful Qualcomm FSM99xx Small Cell Platform, leveraging its advanced feature sets. Airspan has been able to deliver on the promise of 4G small cells to improve indoor and outdoor wireless network capacity and coverage, increasing macro network efficiency and revolutionizing TCO. Airspan is developing 5G RAN solutions, in both Sub-6 GHz and mmWave bands to meet the wide range of challenges experienced today by mobile operators. The products will feature advanced technologies inc

Sartorius Closes Fiscal 2018 Successfully and Aims to Further Expand19.2.2019 16:08:00Tiedote

Sartorius (FWB:SRT), a leading international partner of biopharmaceutical research and the industry, confirmed its preliminary figures with the publication of its 2018 Annual Report. Accordingly, the Group continued on the growth track in both divisions and across all geographies, and thus achieved its forecast raised considerably at mid-year. Group sales revenue rose in constant currencies by 13.2% to 1,566.0 million euros (reported: +11.5%), with the non-organic share of this figure amounting to around one percentage point. The EMEA region (Europe | Middle East | Africa) accounted for 42% of consolidated sales; the Americas, 33%; and Asia | Pacific, 25%. Order intake rose in constant currencies by 12.5% to 1,662.5 million euros. The positive development of the Group is reflected by the organic increase in the number of employees. As at December 31, 2018, a total of 8,125 people were employed at Sartorius worldwide; this was a year-over-year gain of some 600 new employees or 8.3%. “Sa

BOC Group Announces the Release of its Latest BPM Suite: ADONIS NP 6.0 Out Now and Better Than Ever Before!19.2.2019 16:00:00Tiedote

BOC Group has just released the next major version upgrade of its BPM suite ADONIS NP and introduced a great mix of brand new features, enhanced extensions and different technology updates. The new ADONIS NP 6.0 brings meaningful innovation for all users, with a special emphasis on making better decisions faster with the help of Business Process Simulation & Optimization. Providing powerful Process Simulation, the latest release of the Business Transformation Suite ADONIS NP encompasses major new features and cutting-edge capabilities to facilitate, optimize and accelerate digital transformation! It is a step forward into a new era of innovation and simplicity. Tobias Rausch, ADONIS NP product manager says: “Business Process Simulation & Optimization is without a doubt the flagship feature of the new ADONIS NP 6.0. It allows you to visualize, change, slice and dice your processes and test alternatives in a risk-free environment, before taking an actual step change and committing capita

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme